PMID- 27862163 OWN - NLM STAT- MEDLINE DCOM- 20170913 LR - 20210109 IS - 1440-1681 (Electronic) IS - 0305-1870 (Print) IS - 0305-1870 (Linking) VI - 44 IP - 2 DP - 2017 Feb TI - Effects of high-sodium intake on systemic blood pressure and vascular responses in spontaneously diabetic WBN/Kob-Lepr(fa/fa) rats. PG - 305-312 LID - 10.1111/1440-1681.12700 [doi] AB - The prevalence of type 2 diabetes mellitus (T2DM) and hypertension has markedly increased worldwide. The purpose of the present study was to examine the effects of a high-salt intake on the systolic blood pressure (SBP) and vascular responses in WBN/Kob-Lepr(fa/fa) (WBKDF) rats, a new spontaneous animal model of T2DM. Male WBKDF rats and age-matched Wistar rats at 6 weeks of age were each divided into two groups and fed either a normal-sodium (NS, 0.26%) diet or high-sodium (HS, 8%) diet for 14 weeks: (i) Wistar rats on NS diet (Wistar-NS); (ii) Wistar rats on HS diet (Wistar-HS); (iii) WBKDF rats on NS diet (WBKDF-NS); (iv) WBKDF rats on HS diets (WBKDF-HS). Neither WBKDF-NS nor Wistar-NS rats showed significant changes in SBP throughout the experiment, but both WBKDF-HS and Wistar-HS exhibited significant elevation of SBP, which was more prominent (P<.01) in WBKDF-HS than in Wistar-HS. Phenylephrine-induced contractions of isolated thoracic aortic rings were significantly (P<.01) enhanced in WBKDF-HS and Wistar-HS compared with the respective strain of rats on the NS diet. In contrast, acetylcholine- and nitroprusside-induced relaxation were significantly (P<.01) diminished in both WBKDF-HS and Wistar-HS, and these HS diet-induced changes were more profound (P<.01) in WBKDF rats than in Wistar rats. Significantly (P<.05) higher plasma concentrations of 8-iso-prostaglandin F(2alpha) and sodium ions were observed in WBKDF-HS than in Wistar-HS. The current study demonstrated that WBKDF-HS rats developed salt-sensitive hypertension associated with vascular dysfunction. The WBKDF rat may be a useful model for investigating the etiology of hypertension with T2DM. CI - (c) 2016 The Authors. Clinical and Experimental Pharmacology and Physiology Published by John Wiley & Sons Australia, Ltd. FAU - Takagi, Yoshiichi AU - Takagi Y AD - Laboratory of Veterinary Pharmacology, Azabu University, Sagamihara, Kanagawa, Japan. FAU - Kadowaki, Haruno AU - Kadowaki H AD - Laboratory of Veterinary Pharmacology, Azabu University, Sagamihara, Kanagawa, Japan. FAU - Kobayashi, Ikumi AU - Kobayashi I AD - Laboratory of Veterinary Pharmacology, Azabu University, Sagamihara, Kanagawa, Japan. FAU - Ito, Kaoru AU - Ito K AD - Clinical Nutrition, Chiba University Hospital, Chiba, Japan. FAU - Ito, Katsuaki AU - Ito K AD - Laboratory of Veterinary Pharmacology, Azabu University, Sagamihara, Kanagawa, Japan. FAU - Shirai, Mitsuyuki AU - Shirai M AD - Laboratory of Veterinary Pharmacology, Azabu University, Sagamihara, Kanagawa, Japan. FAU - Asai, Fumitoshi AU - Asai F AD - Laboratory of Veterinary Pharmacology, Azabu University, Sagamihara, Kanagawa, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Australia TA - Clin Exp Pharmacol Physiol JT - Clinical and experimental pharmacology & physiology JID - 0425076 RN - 0 (Blood Glucose) RN - 0 (Insulin) RN - 0 (Sodium Chloride, Dietary) SB - IM MH - Animals MH - Animals, Congenic MH - Aorta, Thoracic/drug effects/physiopathology MH - Blood Glucose/analysis MH - Blood Pressure/*drug effects MH - Diabetes Mellitus, Experimental/blood/complications/*physiopathology MH - Diabetes Mellitus, Type 2/blood/complications/*physiopathology MH - Hypertension/etiology MH - Insulin/blood MH - Kidney/pathology/physiopathology MH - Male MH - Obesity/blood/complications/*physiopathology MH - Rats, Wistar MH - Sodium Chloride, Dietary/*adverse effects MH - Vasoconstriction/*drug effects PMC - PMC5299487 OTO - NOTNLM OT - WBN/Kob-Leprfa/fa rat OT - high-sodium diet OT - salt-sensitive hypertension OT - type 2 diabetes mellitus EDAT- 2016/11/20 06:00 MHDA- 2017/09/14 06:00 PMCR- 2017/02/09 CRDT- 2016/11/19 06:00 PHST- 2016/05/18 00:00 [received] PHST- 2016/11/10 00:00 [revised] PHST- 2016/11/10 00:00 [accepted] PHST- 2016/11/20 06:00 [pubmed] PHST- 2017/09/14 06:00 [medline] PHST- 2016/11/19 06:00 [entrez] PHST- 2017/02/09 00:00 [pmc-release] AID - CEP12700 [pii] AID - 10.1111/1440-1681.12700 [doi] PST - ppublish SO - Clin Exp Pharmacol Physiol. 2017 Feb;44(2):305-312. doi: 10.1111/1440-1681.12700.